Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer

By Denduluri Neelima   Lee James   Walshe Janice   Berman Arlene   Vatas Ujala   Chow Catherine   Steinberg Seth   Cox Michael   Low Jennifer   Swain Sandra  

Investigational New Drugs, Vol. 25, Iss. 1, 2007-02 ,pp. : 63-67

Springer Publishing Company

Access to resources Recommend Favorite

A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer

By Wakelee Heather   Fisher George  

Investigational New Drugs, Vol. 23, Iss. 3, 2005-06 ,pp. : 241-242

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer

By Kim Sun   Hong Yong   Kim Byung   Park Ji   Choi Hyo   Jeong Seung-Yong   Kim Dae   Hong Chang   Sohn Dae   Jung Kyung  

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 269-274

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines

By Shitara Kohei  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 787-793

Springer Publishing Company

Access to resources Recommend Favorite

A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy

By Shin Sang  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 672-680

Springer Publishing Company

Access to resources Recommend Favorite